The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors.

中文翻译：

---

一两个免疫检查点抑制剂？

与黑色素瘤和肺癌的标准治疗相比，评估了ipilimumab和nivolumab的组合。对这些试验的分析强调了肿瘤类型之间的结果和潜在的预测性生物标志物的差异，以及与免疫检查点抑制剂的最佳使用有关的多个尚存的问题。